Their oral dosage form and long history of clinical experience make them a mainstay in the treatment of T2DM. Three sulfonylureas are available in the United States—glimepiride, glipizide, and glyburide—and all 3 are roughly clinically interchangeable in terms of hemoglobin A1c (HbA1c) lowering.